Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication CANASA is indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. CANASA is an aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. ( 1 ) FDA label
mesalamine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| mesalamine | DRUG | encapsulated mesalamine granules |
Inclusion Criteria: * The subject is Male, or female of Non-childbearing potentia.l * The subject is female of childbearing potential, who has a negative serum pregnancy test at screen and agrees to using appropriate birth control. * The subject is between the ages of 18 and 45 years. * The subject...
Mesalamine is a small molecule drug being developed by Bausch Health Companies Inc. (ticker BHC). It is in Phase 1 clinical development, and the specific indication has not been disclosed. The program includes one completed Phase 1 pharmacokinetic study conducted in healthy volunteers in the United States.
Mesalamine targets ALOX5, PTGS2, PTGS1, and PPARG. It is classified as an inhibitor of these targets. ALOX5 and PTGS1/PTGS2 are enzymes involved in inflammatory pathways, while PPARG is a nuclear receptor. This target profile is consistent with the drug's classification as a small molecule.
Mesalamine is being developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is the sponsor of the clinical program for this asset.
Mesalamine is in Phase 1 clinical development. It is an investigational drug and is not approved. The program includes one completed Phase 1 trial, and there are currently no active trials listed for this asset.
Mesalamine has been studied in one completed Phase 1 trial, NCT00622375, titled a pharmacokinetic study of encapsulated mesalamine granules in healthy volunteers. The trial enrolled 24 participants in the United States, with an age minimum of 18 years and all sexes eligible. It was an uncontrolled study without randomization or blinding.